Eli Lilly's Sofe-M plus bevacizumab achieves 79% response rate in Phase 1 ovarian cancer trial

• Eli Lilly announced Phase 1 results showing its investigational sofetabart mipitecan with bevacizumab shrank tumors in most patients with platinum-sensitive ovarian cancer.
• Responses were consistent across folate receptor alpha expression levels, including patients previously treated with PARP inhibitors.
• No new safety signals emerged; few patients discontinued treatment because of adverse events.
• Results will be presented at the 2026 European Society for Medical Oncology congress in Madrid.
• The combination is undergoing Phase 3 testing in platinum-sensitive disease; the broader FRAmework-01 program also evaluates monotherapy in platinum-resistant ovarian cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610240230PR_NEWS_USPR_____DE78967) on October 24, 2026, and is solely responsible for the information contained therein.